The Million-Dollar Question: Why GLP-1 Drugs Don’t Work for Everyone
By GLPeak Team · 2026-05-05
Struggling to lose weight on Ozempic or Wegovy? New research reveals the genetic GLP-1 resistance affecting 1 in 10 people—and what this means for patients.
For years, medications like Ozempic, Wegovy, and Mounjaro have been hailed as a revolutionary "one-size-fits-all" solution for type 2 diabetes and obesity. However, clinical experience has shown that a segment of the population simply doesn't respond to these treatments as expected. A new study from Stanford Medicine, published in Genome Medicine in March 2026, has finally shed light on why: GLP-1 resistance.
This research marks a significant transition in how we understand metabolic health, moving us away from a trial-and-error approach and toward a future with a more personalized, genetic-based model of care.
The 10% Factor: Genetic Resistance
The Stanford researchers discovered that roughly one in ten people carry specific genetic variants that decrease the ability of GLP-1 medications to regulate blood sugar. Specifically, the study identified variants that handicap an enzyme known as PAM (peptidyl-glycine alpha-amidating monooxygenase).
This enzyme is responsible for activating several hormones in the body, including natural GLP-1. In a surprising turn, researchers found that people with these PAM variants actually have higher levels of natural GLP-1 in their blood, but the hormone is seemingly less effective. Much like insulin resistance, where the body has plenty of insulin but can't use it, GLP-1 resistance means the body’s receptors are essentially less sensitive to the hormone’s signals.
Clinical Impact: Blood Sugar
The study’s findings have immediate implications for patients managing type 2 diabetes. In a meta-analysis of clinical trials, Stanford scientists found:
Only 11.5% of patients with the specific genetic variant reached their HbA1c target after six months of treatment.
In contrast, roughly 25% of those without the variant reached their target in the same timeframe.
Interestingly, it is not yet clear if this genetic resistance affects weight loss to the same degree as blood sugar regulation. However, for those using the medication for glucose control, the resistance is a significant barrier to success.
Gastric Emptying Connection
A key function of GLP-1 medications is to slow down gastric emptying, the process by which food moves from the stomach into the small intestine. The Stanford team found that mice lacking the PAM gene had significantly faster gastric emptying.
This suggests that GLP-1 resistance isn't just about how the body processes sugar; it's a difference in how the digestive system responds. For these patients, the feeling of fullness that defines the GLP-1 experience may never fully materialize, making it much harder to maintain the caloric deficit required for weight loss or the steady glucose levels needed for diabetes management.
Looking Ahead: GLP-1 Sensitizers
The discovery of GLP-1 resistance is a breakthrough because it identifies a new target for drug development. Just as the medical community developed insulin sensitizers for people with type 2 diabetes, the future of metabolic medicine may include GLP-1 sensitizers.
These future treatments could potentially be used in combination with current medications to help resensitize the body to GLP-1 signals. Alternatively, different delivery methods or formulations might be developed specifically to bypass the limitations caused by the PAM variant.
The Path to Personalized Nutrition
The most important takeaway for patients is that if a GLP-1 medication isn't working for you, it may not be a failure of willpower or lifestyle. Understanding this allows us to stop trying to force a round peg into a square hole. It opens the door to looking at different tools, such as medications that target different hormones like GIP or glucagon. Success is not about making one specific drug work; it is about finding the combination of habits and tools that lead to a sustainable, healthy baseline.
Umapathysivam, M.M., Araldi, E., Hastoy, B. et al. Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists. Genome Med 18, 40 (2026). https://doi.org/10.1186/s13073-026-01630-0